Abstract

Inhibition of the Cyclin-Dependent Kinases (CDK) 4/6 as Therapy for Estrogen Receptor Positive Breast Cancer

Endocrine therapy (ET) is the usual first-line therapy for patients with hormone receptor-positive metastatic breast cancer (HR+MBC). However, resistance to ET frequently occurs during the course of treatment. Cellular pathways involved in cell proliferation are targets for new drugs that interfere with development of resistance to ET. Cyclin-dependent kinases (CDKs) are a subgroup of serine/ threonine kinases that play a key role in regulating cell cycle progression. In this review, we discuss the currently approved and under investigation CDK 4/6 inhibitors, in addition to their preclinical data and clinical trials that demonstrated their benefit in the treatment of HR+ breast cancer.


Author(s):

Aurelio B Castrellon, Steven M Nguyen and Luis E Raez



Abstract | Full-Text | PDF

Share this  Facebook  Twitter  LinkedIn  Google+

Recommended Conferences

  • 23rd International Conference on Cancer Research & Pharmacology
    March 26-27, 2018, Edinburgh, Scotland
  • Cancer Genomics Conference: New Era for Cancer Prevention
    June 25-26, 2018 Dubai, UAE
  • 28th International Conference on Cancer Research and Anticancer Therapies
    September 17-18, 2018 San Diego, California, USA
  • Annual Congress on Cancer and Stem Cell Research
    October 19-20, 2018 Baltimore, Maryland, USA
Flyer image

Abstracted/Indexed in

  • Google Scholar
  • CiteFactor
  • WorldCat
  • Publons
  • Geneva Foundation for Medical Education and Research